About Us
An AI-powered end-to-end precision cancer diagnostics platform.
Immuno-Oncology & ADCs: The Importance of the Tumor Microenvironment
Advancing therapeutic response prediction through spatial context analysis
Paradigm Shift
Therapeutic strategies are rapidly evolving from chemical and targeted therapies to IO and ADC-based treatments.
Clinical Limitations
Single-biomarker-based predictions show limited response rates of only 20–30%, highlighting the need for more advanced analysis.
Market Demand
Demand for spatial biology technologies that analyze cellular positioning and interactions within the TME is rapidly increasing.
From Validation to Expansion to Commercialization
Founded by Asan Medical Center faculty, comprised of experts in bio-medical commercialization.
• 16 R&D experts (MD/PhD) in medical and life sciences • 2 global business experts (Ex-GC Biopharma, etc.) • Contributed to 80%+ of top domestic Multiplex IHC publications
Sang-Yeob Kim
Chief Executive Officer (CEO)
Director, Bioimaging Center, Asan Medical Center Core Faculty, Optical Imaging Analysis Lab 120+ SCI(E)-Indexed Publications
Kyung-Chul Woo
Chief Technology Officer (CTO)
Former Head of Research Institute, New Life Group Head of R&D & Technology Business Division Lead Developer of TimeCell Product Line KRW 300B Cumulative Sales